ストックスクリーナーアプリを入手
38.66
0.49%
-0.19
前日終値:
$38.85
開ける：
$38.94
24時間の取引高:
414.83K
Relative Volume:
0.96
時価総額：
$783.34M
収益：
$1.77M
当期純損益:
$-123.74M
株価収益率:
-4.2159
EPS:
-9.17
ネットキャッシュフロー:
$-95.21M
1週間 パフォーマンス:
+4.15%
1か月 パフォーマンス:
-40.55%
6か月 パフォーマンス:
-33.15%
1年 パフォーマンス:
-36.64%
1日の値動き範囲:
$38.13
$39.60
1週間の範囲:
$33.10
$39.60
52週間の値動き範囲:
$33.01
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
名前
Praxis Precision Medicines Inc
セクター
電話
617-300-8460
住所
99 HIGH STREET, 30TH FLOOR, BOSTON
PRAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
38.66 | 783.34M | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-08-05 | 開始されました | Oppenheimer | Outperform |
| 2024-06-24 | 開始されました | Needham | Buy |
| 2024-06-18 | 開始されました | Guggenheim | Buy |
| 2024-05-01 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-19 | 開始されました | Truist | Buy |
| 2022-06-06 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2021-08-26 | 開始されました | BofA Securities | Buy |
| 2021-04-26 | 開始されました | William Blair | Outperform |
| 2020-11-11 | 開始されました | Wedbush | Outperform |
| 2020-11-10 | 開始されました | Cowen | Outperform |
| 2020-11-10 | 開始されました | Evercore ISI | Outperform |
| 2020-11-10 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Praxis Precision Medicines Inc (PRAX) 最新ニュース
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by Swiss National Bank - Defense World
Praxis Precision Medicines to Present Late-Stage Data on CNS Disorders at AAN 2025 Annual Meeting - Nasdaq
Praxis Precision Medicines to Present on Late-Stage - GlobeNewswire
Major Clinical Updates: Praxis Unveils Late-Stage Data for Epilepsy and Movement Disorders at AAN 2025 - StockTitan
Charles Schwab Investment Management Inc. Acquires 5,840 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Bank of New York Mellon Corp - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by US Bancorp DE - Defense World
HC Wainwright Has Negative Estimate for PRAX Q1 Earnings - Defense World
Praxis Precision Medicines Updates on Programs and Finances - TipRanks
New York State Common Retirement Fund Boosts Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Rhumbline Advisers Cuts Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year Low Following Analyst Downgrade - Defense World
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Adds Six New Hires With $33.55 Stock OptionsWhat's Behind This Talent Acquisition? - StockTitan
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences - GlobeNewswire
Praxis Precision price target lowered to $85 from $150 at Needham - Yahoo Finance
CNS Therapy Developer PRAX Lines Up Five Major Investor ConferencesWhat's Their 2025 Strategy? - StockTitan
Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide (NASDAQ:PRAX) - Seeking Alpha
Praxis Precision Medicines (NASDAQ:PRAX) Given New $105.00 Price Target at HC Wainwright - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Cut to $85.00 by Analysts at Needham & Company LLC - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Given New $73.00 Price Target at Robert W. Baird - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Lowered to $85.00 at Truist Financial - Defense World
Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade) - Seeking Alpha
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate - Benzinga India
Praxis Precision (PRAX) Stock Price Target Cut By Half - AskTraders
Praxis Precision price target lowered to $85 from $175 at Truist - TipRanks
Praxis Precision Medicines Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Praxis Precision tanks on negative ulixacaltamide news - The Pharma Letter
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $65 From $111, Maintains Buy Rating - Marketscreener.com
Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts - Benzinga
Praxis Precision Medicines: A Compelling Buy Amidst Promising Pipeline Developments - TipRanks
Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down After Earnings Miss - Defense World
Praxis Precision Medicines (PRAX) Projected to Post Quarterly Earnings on Friday - MarketBeat
Praxis cites doubts over late-stage trial success: Wedbush downgrades (update) - MSN
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update - GlobeNewswire
Praxis to advance late-stage program for lead asset despite doubts over success - MSN
Praxis stock price target cut to $61 at TD Cowen By Investing.com - Investing.com Australia
Items Tagged with 'relutrigine' - BioWorld Online
Items Tagged with 'vormatrigine' - BioWorld Online
Praxis Aims To Complete ET Trial Despite Likely Primary Endpoint Miss - Citeline News & Insights
Praxis stock price target cut to $61 at TD Cowen - Investing.com India
Wedbush Downgrades Praxis Precision Medicines to Underperform From Neutral, Cuts Price Target to $26 From $57; Shares Fall - Marketscreener.com
Market Whales and Their Recent Bets on PRAX OptionsPraxis Precision Medicine (NASDAQ:PRAX) - Benzinga
H.C. Wainwright sees opportunity for quick rebound from Praxis after setback - TipRanks
Truist cuts Praxis stock target to $85, maintains buy rating By Investing.com - Investing.com South Africa
Truist cuts Praxis stock target to $85, maintains buy rating - Investing.com
Praxis Precision Medicines: Navigating Challenges and Catalysts in Epilepsy Treatment - TipRanks
Buy Rating Maintained for Praxis Precision Medicines Despite Essential3 Setback, Focus on Promising Pipeline and Strong Financial Position - TipRanks
Truist Securities Adjusts Praxis Precision Medicines Price Target to $85 From $175, Maintains Buy Rating; Shares Plunge - Marketscreener.com
Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines - TradingView
Praxis Precision Medicines Inc (PRAX) 財務データ
収益
当期純利益
現金流量
EPS
Praxis Precision Medicines Inc (PRAX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Sale |
80.20 |
8,239 |
660,827 |
10,301 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Option Exercise |
56.94 |
4,374 |
249,056 |
10,801 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Sale |
81.78 |
5,188 |
424,318 |
5,613 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):